News 2017 – Levine Media Group

October 10, 2017
A Rare Breed: How people and perseverance built BioMarin into one of the world's most innovative companies
The history of BioMarin Pharmaceutical authored by Daniel S. Levine and Daniel P. Maher is now available.

Spetember 20, 2017
Treos Bio Enters into Agreement with PPD to Manage First-in-Man Trial of Its Lead Therapeutic Cancer Vaccine Program
SAN FRANCISCO, CA and LONDON, UNITED KINGDOM--(Marketwired - Sep 20, 2017) - Treos Bio Limited, which is developing precision peptide cancer vaccines coupled with companion diagnostics, today announced it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization. As part of the agreement, PPD® Biotech, a PPD service dedicated to biotech and small to mid-sized pharmaceutical companies, will manage Treos Bio's first-in-man study of its lead therapeutic cancer vaccine for metastatic colorectal cancer. This study will be conducted in the United States and Europe.

August 22, 2017
RARE Webinar: Building the Bridge between Foundations and Industry
Are you a foundation looking for an industry partner? How about a biotech/pharma company looking to know about your patient community? This can be a tough gap to fill between these two worlds. How do you start? Who do you talk to? Learn the tricks to go build your own bridge and find out from a foundation and industry partnership the ins and outs of building and maintaining a relationship between these two industries. Levine Media Group's Daniel Levine moderates.

June 20, 2017
BIO International Convention - San Diego: Simple in Theory, Difficult in Practice: Entering a New Era of Enzyme Replacement Therapy for Rare Genetic Diseases
The enzyme replacement therapy market has surpassed $4 billion, which is based on the premise of replacing the missing or dysfunctional enzyme in patients with diseases. While this approach has proven to be successful in diseases in which recombinant enzymes are able to correct the disease when administered intravenously, it is not a viable option for many rare, inherited diseases in which the missing enzyme needing to be replaced is inside the targeted cell. As we enter the age of genomic medicine, exciting new advancements in mRNA therapeutics are opening doors to next-generation enzyme replacement therapies that are able to correct these types of intracellular enzyme deficiencies. This session will hear from industry insiders as they discuss their approaches for replacing missing enzymes where the biology is difficult to access. Levine Media Group's Daniel Levine moderates.

June 13, 2017
RARE Webinar: Make Sense of Your Dollars
A rare disease diagnosis is something that no one can plan or prepare for and it can often lead to financial burdens, but with the right guidance in financial planning, you can overcome these budgeting obstacles. Listen in to hear professionals in finance guide you through money management and budget preparation. Levine Media Group's Daniel Levine moderates.

May 15, 2017
Advancing Rare Disease Drug Discovery: Navigating the Path to an IND
Therapies to treat rare and undiagnosed diseases are in high demand in a favorable regulatory environment. Thus, it is critically important to optimize the discovery and development of such therapies by creating – and following – the most efficient path to an investigational new drug (IND) filing. How do we do just that? In-depth scientific investigation, combined with efficiently planned study paradigms, are key to moving therapeutics along the drug development continuum. Charles River Labs hosts a day-long seminar at the Boston Marriott Cambridge in Cambridge, Mass. Levine Media Group’s Daniel Levine moderates.

April 25, 2017
Treos Bio Names Group of Leading Clinical and Regulatory Experts to Clinical Advisory Board
Members’ deep expertise will guide company as it advances its pipeline into clinical trials
SAN FRANCISCO, CA and LONDON, UNITED KINGDOM–(Marketwired – Apr 25, 2017) – Treos Bio, which is developing precision therapeutic cancer vaccines as well as companion diagnostics, today announced the appointment of a group of leading experts to its newly established Clinical Advisory Board.

April 12, 2017
Amfora Raises $5 Million in Series A Venture Round
Biotech company will use the funding to accelerate the development of crops for improved human and animal nutrition
SAN FRANCISCO - Apr 12, 2017 - Amfora Inc., a biotech start-up focused on developing crops with enhanced nutritional content, today announced the closing of a Series A financing. San Francisco-based Spruce Capital, co-manager of the MLS Fund II, led the round, which included participation from The Commonwealth Scientific Industrial Research Organization (CSIRO), the globally renowned Australian-based national science agency.

April 3, 2017
Treos Bio Announces Filing of Key Patent Applications on its Precision Therapeutic Cancer Vaccine Development Platform and its Compositions for Colorectal and Breast Cancers
SAN FRANCISCO, CA and LONDON, UNITED KINGDOM–(Marketwired – Apr 3, 2017) – Treos Bio, which is developing precision therapeutic cancer vaccines coupled with companion diagnostics, today announced it has completed filing of two patent applications with the European Patent Office. These applications are protecting Treos’ Precision Therapeutic Cancer Vaccine Development Platform as well as the compositions of its colorectal and breast cancer vaccines.

March 21, 2017
Precision Therapeutic Cancer Vaccine Developer Treos Bio Opens U.S. Headquarters in San Francisco
Names Dong Wei, Ph.D., MBA, as its Chief Operating Officer
SAN FRANCISCO, CA and LONDON, UNITED KINGDOM–(Marketwired – Mar 21, 2017) – Treos Bio Limited, which is developing precision therapeutic cancer vaccines coupled with companion diagnostics, today announced it has established U.S. headquarters in San Francisco’s financial district and has named Dong Wei, Ph.D., MBA, an experienced biopharmaceutical executive, as its chief operating officer. Dr. Wei brings a combination of experiences in early- and late-stage biopharmaceutical development, business operations, and strategic planning to Treos.

February 1, 2017
RARE Webinar: Health Insurance 101
Anyone can tell you that navigating insurance is no easy task. Whether you have no medical needs or have an abundant, learning definitions, healthcare plans and the appeal process call for a basic guide. Find your go to guide on our webinar where you will get to hear from experts in insurance and learn how to read an insurance plan, navigate the insurance system, and get the benefits you need in order to manage your rare disease. Levine Media Groups Daniel Levine moderates.

February 3, 2017
Treos Bio Raises $8 Million in Private Investment Round
Funding will carry company through early-stage clinical trial of its precision vaccine for colorectal cancer
SAN FRANCISCO, CA and LONDON, UNITED KINGDOM–(Marketwired – Feb 13, 2017) – Treos Bio, Ltd., which is developing precision cancer immunotherapies paired to companion diagnostics, today announced it completed an $8 million funding through a group of private investors.

January 5, 2017
TechHistoryWorks, Science History Consultants, and Levine Media Group Form Alliance
Groups will collaborate to help biotech and high-tech companies preserve and tell their stories
SAN FRANCISCO—JANUARY 5, 2017—TechHistoryWorks, Science History Consultants, and Levine Media Group today announced an alliance to help high-tech and life sciences companies capture and share their stories. Science History Consultants is a corporate history firm established 32 years ago in Philadelphia. The Levine Media Group specializes in creating content for the life sciences industry. TechHistoryWorks will combine their strengths.

Older news